
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corp has demonstrated strong performance with driver shipments of 65,000 units, exceeding expectations and reflecting an 8% quarter-over-quarter and 11% year-over-year increase. The company's gross margin improved by 240 basis points year-over-year, while the operating margin saw a significant increase of 570 basis points, indicating effective operational efficiencies and favorable product mix. Additionally, management has reaffirmed revenue guidance for 2025 at an 8-11% growth rate and raised their EPS guidance, highlighting confidence in continued strong financial performance and potential for organic revenue growth driven by market share gains and new product developments.
Bears say
The financial analysis reveals a negative outlook for Masimo Corp, primarily due to a slowdown in healthcare growth and declining revenues across both healthcare and non-healthcare segments. Revenue estimates for 2025 and 2026 have been significantly reduced, reflecting expectations of mid-single-digit growth and the removal of the non-healthcare business from projections, indicating a weakening market position. Furthermore, challenges such as manufacturing issues, supply chain disruptions, and potential impacts from GLP-1 weight loss drugs are likely to hinder operational margins and overall financial performance.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares